FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2787074016> ?p ?o ?g. }

• W2787074016 endingPage "733" @default.
• W2787074016 startingPage "728" @default.
• W2787074016 abstract "•Statins and/or proprotein convertase subtilisin/kexin type 9 antibodies do not increase or decrease the rate of cataract. •No difference of statin vs proprotein convertase subtilisin/kexin type 9 treatment with respect to cataract was seen. •Very low levels of low-density lipoprotein cholesterol are not associated with the development of cataract. •Fear of cataract should not prevent the use of cholesterol-lowering therapy. Background It is not known whether statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies are associated with cataract and whether very low achieved low-density lipoprotein cholesterol (LDL-C) lowering may cause cataract. Objective To examine two questions: whether statins and/or PCSK9 antibodies cause or prevent cataracts and whether very low LDL-C is associated with increased risk of cataract. Methods Systematic searches of PubMed, ClinicalTrials.gov, Web of Science, The Cochrane Library, and an Federal Drug Administration report were used to perform random effects meta-analyses on the relationship of statins and/or PCSK9 antibodies with cataract. These meta-analyses were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results Prespecified analyses indicated no significant effect of statins or PCSK9 antibodies (odds ratio [OR] 0.99, 95% confidence interval [CI] 0.83–1.17, P = .8889) or differences between the effects of statins (OR 0.89, 95% CI 0.66–1.19, P = .4349) and PCSK9 antibodies (OR 1.04, 95% CI 0.85–1.28, P = .7042) on the development of cataract. Also, there was no significant effect of LDL-C lowering to different levels with respect to cataract (OR 1.06, 95% CI 0.92–1.22, P = .4317). Meta-regression of the log OR for cataract vs LDL-C during treatment did not show a statistically significant relationship (P for slope = .3972). Conclusion There was no significant effect of cholesterol lowering with statins or PCSK9 antibodies or differences between these two medication classes in causing or preventing cataracts. However, it is difficult to make definitive statements regarding PCSK9 antibodies because there is no long-term experience with these agents. Very low LDL-C was not associated with higher risk of cataract. It is not known whether statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies are associated with cataract and whether very low achieved low-density lipoprotein cholesterol (LDL-C) lowering may cause cataract. To examine two questions: whether statins and/or PCSK9 antibodies cause or prevent cataracts and whether very low LDL-C is associated with increased risk of cataract. Systematic searches of PubMed, ClinicalTrials.gov, Web of Science, The Cochrane Library, and an Federal Drug Administration report were used to perform random effects meta-analyses on the relationship of statins and/or PCSK9 antibodies with cataract. These meta-analyses were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Prespecified analyses indicated no significant effect of statins or PCSK9 antibodies (odds ratio [OR] 0.99, 95% confidence interval [CI] 0.83–1.17, P = .8889) or differences between the effects of statins (OR 0.89, 95% CI 0.66–1.19, P = .4349) and PCSK9 antibodies (OR 1.04, 95% CI 0.85–1.28, P = .7042) on the development of cataract. Also, there was no significant effect of LDL-C lowering to different levels with respect to cataract (OR 1.06, 95% CI 0.92–1.22, P = .4317). Meta-regression of the log OR for cataract vs LDL-C during treatment did not show a statistically significant relationship (P for slope = .3972). There was no significant effect of cholesterol lowering with statins or PCSK9 antibodies or differences between these two medication classes in causing or preventing cataracts. However, it is difficult to make definitive statements regarding PCSK9 antibodies because there is no long-term experience with these agents. Very low LDL-C was not associated with higher risk of cataract." @default.
• W2787074016 created "2018-02-23" @default.
• W2787074016 creator A5005933614 @default.
• W2787074016 creator A5010988550 @default.
• W2787074016 creator A5012557821 @default.
• W2787074016 creator A5024728467 @default.
• W2787074016 creator A5076530618 @default.
• W2787074016 date "2018-05-01" @default.
• W2787074016 modified "2023-10-10" @default.
• W2787074016 title "Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis" @default.
• W2787074016 cites W1874026010 @default.
• W2787074016 cites W1964435302 @default.
• W2787074016 cites W1978205439 @default.
• W2787074016 cites W2012789522 @default.
• W2787074016 cites W2023168258 @default.
• W2787074016 cites W2064328378 @default.
• W2787074016 cites W2095126661 @default.
• W2787074016 cites W2133945578 @default.
• W2787074016 cites W2135163001 @default.
• W2787074016 cites W2157664837 @default.
• W2787074016 cites W2157823046 @default.
• W2787074016 cites W2164670352 @default.
• W2787074016 cites W2200285648 @default.
• W2787074016 cites W2313998826 @default.
• W2787074016 cites W2582372330 @default.
• W2787074016 cites W2596236174 @default.
• W2787074016 cites W2596676407 @default.
• W2787074016 cites W2605085471 @default.
• W2787074016 cites W2621671248 @default.
• W2787074016 cites W2748800769 @default.
• W2787074016 cites W3022903699 @default.
• W2787074016 doi "https://doi.org/10.1016/j.jacl.2018.02.002" @default.
• W2787074016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29501393" @default.
• W2787074016 hasPublicationYear "2018" @default.
• W2787074016 type Work @default.
• W2787074016 sameAs 2787074016 @default.
• W2787074016 citedByCount "11" @default.
• W2787074016 countsByYear W27870740162018 @default.
• W2787074016 countsByYear W27870740162019 @default.
• W2787074016 countsByYear W27870740162020 @default.
• W2787074016 countsByYear W27870740162021 @default.
• W2787074016 countsByYear W27870740162022 @default.
• W2787074016 countsByYear W27870740162023 @default.
• W2787074016 crossrefType "journal-article" @default.
• W2787074016 hasAuthorship W2787074016A5005933614 @default.
• W2787074016 hasAuthorship W2787074016A5010988550 @default.
• W2787074016 hasAuthorship W2787074016A5012557821 @default.
• W2787074016 hasAuthorship W2787074016A5024728467 @default.
• W2787074016 hasAuthorship W2787074016A5076530618 @default.
• W2787074016 hasConcept C118487528 @default.
• W2787074016 hasConcept C126322002 @default.
• W2787074016 hasConcept C2776839432 @default.
• W2787074016 hasConcept C2778163477 @default.
• W2787074016 hasConcept C2778824825 @default.
• W2787074016 hasConcept C2778849439 @default.
• W2787074016 hasConcept C2780072125 @default.
• W2787074016 hasConcept C2780225610 @default.
• W2787074016 hasConcept C2780948078 @default.
• W2787074016 hasConcept C43554185 @default.
• W2787074016 hasConcept C71924100 @default.
• W2787074016 hasConcept C90924648 @default.
• W2787074016 hasConcept C95190672 @default.
• W2787074016 hasConceptScore W2787074016C118487528 @default.
• W2787074016 hasConceptScore W2787074016C126322002 @default.
• W2787074016 hasConceptScore W2787074016C2776839432 @default.
• W2787074016 hasConceptScore W2787074016C2778163477 @default.
• W2787074016 hasConceptScore W2787074016C2778824825 @default.
• W2787074016 hasConceptScore W2787074016C2778849439 @default.
• W2787074016 hasConceptScore W2787074016C2780072125 @default.
• W2787074016 hasConceptScore W2787074016C2780225610 @default.
• W2787074016 hasConceptScore W2787074016C2780948078 @default.
• W2787074016 hasConceptScore W2787074016C43554185 @default.
• W2787074016 hasConceptScore W2787074016C71924100 @default.
• W2787074016 hasConceptScore W2787074016C90924648 @default.
• W2787074016 hasConceptScore W2787074016C95190672 @default.
• W2787074016 hasIssue "3" @default.
• W2787074016 hasLocation W27870740161 @default.
• W2787074016 hasLocation W27870740162 @default.
• W2787074016 hasOpenAccess W2787074016 @default.
• W2787074016 hasPrimaryLocation W27870740161 @default.
• W2787074016 hasRelatedWork W2040081726 @default.
• W2787074016 hasRelatedWork W2138544596 @default.
• W2787074016 hasRelatedWork W2522069865 @default.
• W2787074016 hasRelatedWork W2796183245 @default.
• W2787074016 hasRelatedWork W3030723549 @default.
• W2787074016 hasRelatedWork W3093360283 @default.
• W2787074016 hasRelatedWork W4302167071 @default.
• W2787074016 hasRelatedWork W4310335042 @default.
• W2787074016 hasRelatedWork W4323058476 @default.
• W2787074016 hasRelatedWork W4382182823 @default.
• W2787074016 hasVolume "12" @default.
• W2787074016 isParatext "false" @default.
• W2787074016 isRetracted "false" @default.
• W2787074016 magId "2787074016" @default.
• W2787074016 workType "article" @default.